Cargando…

Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study

The aim of this study was to understand current trends in trastuzumab use in China as a neoadjuvant/adjuvant therapy for human epidermal growth factor receptor-2 positive (HER2+) breast cancer and identify factors influencing trastuzumab use. This was a retrospective, multicenter, cross-sectional st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Junjie, Shao, Zhimin, Xu, Binghe, Jiang, Zefei, Cui, Shude, Zhang, Jin, Liao, Ning, Jiang, Jun, Wang, Yongsheng, Ouyang, Quchang, Ying, Ziwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393039/ https://www.ncbi.nlm.nih.gov/pubmed/29794725 http://dx.doi.org/10.1097/MD.0000000000010350

Ejemplares similares

Outcomes of re-treatment with first-line trastuzumab plus a taxane in HER2 positive metastatic breast cancer patients after (neo)adjuvant trastuzumab: A prospective multicenter study
por: Xu, Binghe, et al.
Publicado: (2016)

Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial
por: Huang, Liang, et al.
Publicado: (2015)

Trastuzumab in the Adjuvant Treatment of HER2-Positive Early Breast Cancer Patients: A Meta-Analysis of Published Randomized Controlled Trials
por: Yin, Wenjin, et al.
Publicado: (2011)

Efficacy and safety of everolimus in combination with trastuzumab and paclitaxel in Asian patients with HER2+ advanced breast cancer in BOLERO-1
por: Toi, Masakazu, et al.
Publicado: (2017)

Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial
por: Wu, Jiong, et al.
Publicado: (2022)

Effect of adjuvant trastuzumab among patients treated with anti-HER2-based neoadjuvant therapy
por: Gonzalez-Angulo, A M, et al.
Publicado: (2015)

Pyrotinib versus trastuzumab emtansine for HER2-positive metastatic breast cancer after previous trastuzumab and lapatinib treatment: a real-world study
por: Li, Feng, et al.
Publicado: (2021)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
por: Palmieri, Carlo, et al.
Publicado: (2015)

BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer
por: Dang, Chau, et al.
Publicado: (2022)

Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab: A real-world study
por: Zhao, Wei, et al.
Publicado: (2020)

HER4 expression status correlates with improved outcome in both neoadjuvant and adjuvant Trastuzumab treated invasive breast carcinoma
por: Portier, Bryce P, et al.
Publicado: (2013)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
por: Vieira, Cláudia, et al.
Publicado: (2022)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Predictive factors of pathologic complete response in HER2-positive and axillary lymph node positive breast cancer after neoadjuvant paclitaxel, carboplatin plus with trastuzumab
por: Ding, Jinhua, et al.
Publicado: (2017)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Real world evidence of adjuvant trastuzumab in HER2 positive early breast cancer
por: Lluch-Gómez, J., et al.
Publicado: (2023)

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
por: Lammers, Philip E., et al.
Publicado: (2018)

Adjuvant trastuzumab and vinorelbine for early-stage HER2+ breast cancer
por: McLaughlin, Shannon, et al.
Publicado: (2023)

Therapeutic Effect of Trastuzumab in Neoadjuvant-Treated HER2-Positive Breast Cancer with Low Infiltrating Level of Tumor-Infiltrating Lymphocytes
por: Liu, Shiwei, et al.
Publicado: (2020)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani, Pooja, et al.
Publicado: (2015)

Effect of the HER-2/CEP17 ratio in IHC 2+/FISH-amplified breast cancer on pathological complete response to neoadjuvant pertuzumab and trastuzumab treatment—a retrospective cohort study
por: Wang, Jiabin, et al.
Publicado: (2022)

PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
por: Pondé, Noam, et al.
Publicado: (2019)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Neoadjuvant Trastuzumab and Pertuzumab for Early HER2-Positive Breast Cancer: A Real World Experience
por: Hall, Benjamin James, et al.
Publicado: (2022)

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
por: Wang, Lize, et al.
Publicado: (2021)

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
por: Cheng, Huan, et al.
Publicado: (2014)

Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE
por: Loibl, Sibylle, et al.
Publicado: (2022)

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis
por: Han, Yiqun, et al.
Publicado: (2019)

Benefits of neoadjuvant therapy compared with adjuvant chemotherapy for the survival of patients with HER2-positive breast cancer: A retrospective cohort study at FUSCC
por: Zheng, Shuyue, et al.
Publicado: (2022)

Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy
por: Cao, Lu, et al.
Publicado: (2016)

Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
por: Sardesai, Sagar, et al.
Publicado: (2020)

Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report
por: Xie, Ning, et al.
Publicado: (2021)

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer()
por: Harbeck, Nadia
Publicado: (2022)

Nab-paclitaxel and trastuzumab combination: a promising approach for neoadjuvant treatment in HER2-positive breast cancer
por: Ricciardi, Giuseppina Rosaria Rita, et al.
Publicado: (2016)

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
por: Ma, Fei, et al.
Publicado: (2023)

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study
por: Simoens, Steven, et al.
Publicado: (2021)

HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer
por: Green, Andrew R., et al.
Publicado: (2014)

HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens
por: Laas, Enora, et al.
Publicado: (2021)

HER2-targeted regimens after prior trastuzumab for patients with HER2-positive unresectable, locally advanced or metastatic breast cancer: a network meta-analysis of randomized controlled trials
por: Li, Xinghui, et al.
Publicado: (2020)

Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
por: Bianchini, Giampaolo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_coge30vg1alrqllciogge08hf0